Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx is a biopharmaceutical company focused on bringing novel products to patients with serious rare and ultra-rare genetic diseases, particularly those with high unmet medical need, well-understood biology, and typically no approved therapy that treats the underlying disease. It was founded in April 2010 by its President and CEO, Emil Kakkis, M.D., Ph.D. Its strategy emphasizes time- and cost-efficient development, running multiple clinical programs in parallel, in-licensing promising candidates from academic institutions and pharmaceutical partners, and generally retaining global commercialization rights.

The portfolio spans four modalities: biologics, small molecules, AAV gene therapy, and nucleic acids. Approved products are Crysvita (a monoclonal antibody targeting FGF23 for X-linked hypophosphatemia and tumor-induced osteomalacia, developed and commercialized globally with Kyowa Kirin), Mepsevii (an enzyme replacement therapy for MPS VII, licensed from Saint Louis University), Dojolvi (an oral synthetic triglyceride for long-chain fatty acid oxidation disorders, licensed from Baylor Research Institute), and Evkeeza (an ANGPTL3-blocking antibody for homozygous familial hypercholesterolemia, licensed from Regeneron, which markets it in the U.S.). Evkeeza is also approved in the EEA, Brazil, Mexico, and Japan. Clinical candidates include UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA) licensed from Abeona, for which the FDA issued an Incomplete Response Letter in February 2026 on a resubmitted BLA. DTX401, an AAV8 gene therapy for glycogen storage disease type Ia, has a completed rolling BLA with an expected PDUFA date in the third quarter of 2026. GTX-102, an antisense oligonucleotide for Angelman syndrome licensed from GeneTx, is in the Phase 3 Aspire study (data expected in the second half of 2026) and the Phase 2/3 Aurora study. DTX301, an AAV8 gene therapy for OTC deficiency licensed from REGENXBIO, is in the Phase 3 Enh3ance study.

The company serves small patient populations with rare genetic conditions. Estimates in the text include about 48,000 XLH patients, 200 MPS VII patients, 8,000 to 14,000 LC-FAOD patients, 6,000 GSDIa patients, 10,000 OTC deficiency patients, and 60,000 Angelman syndrome patients in the developed world. It seeks to commercialize products across the developed world, including North America, the EU, the U.K., Latin America, Türkiye, Asia, and select international markets. It uses its own specialized commercial organization in these markets and a network of third-party distributors in smaller ones.

Operationally, the company relies on collaboration and license agreements with academic institutions and pharmaceutical partners, including Kyowa Kirin, Regeneron, Abeona, GeneTx, REGENXBIO, Saint Louis University, and Baylor Research Institute. Several programs have received FDA and EMA designations such as Orphan Drug, Fast Track, RMAT, Breakthrough Therapy, and PRIME. The text does not describe suppliers, manufacturing, competitors, or headquarters.